Format

Send to

Choose Destination
JAMA. 2015 Apr 7;313(13):1336-46. doi: 10.1001/jama.2015.2323.

Bivalirudin vs heparin with or without tirofiban during primary percutaneous coronary intervention in acute myocardial infarction: the BRIGHT randomized clinical trial.

Author information

1
General Hospital of Shenyang Military Region, Shenyang, Liaoning Province, China.
2
Luhe Hospital, Capital Medical University, Beijing, China.
3
The First Hospital of Jilin University, Changchun, Jilin Province, China.
4
No. 463 Hospital of PLA, Shenyang, Liaoning Province, China.
5
Wuhan Asia Heart Hospital, Wuhan, Hubei Province, China.
6
General Hospital of People's Liberation Army, Beijing, China.
7
Nanjing First Hospital, Nanjing, Jiangsu Province, China.
8
Affiliated Hospital of Logistics University of CAPF, Tianjin, China.
9
The Third Hospital of Jilin University, Changchun, Jilin Province, China.
10
Guangdong General Hospital, Guangdong Province, China.
11
No. 210 Hospital of PLA, Dalian, Liaoning Province, China.
12
Fu Wai Hospital, National Center for Cardiovascular Diseases, Beijing, China.
13
Columbia University Medical Center and the Cardiovascular Research Foundation, New York, New York.

Abstract

IMPORTANCE:

The safety and efficacy of bivalirudin compared with heparin with or without glycoprotein IIb/IIIa inhibitors in patients with acute myocardial infarction (AMI) undergoing primary percutaneous coronary intervention (PCI) are uncertain.

OBJECTIVE:

To determine if bivalirudin is superior to heparin alone and to heparin plus tirofiban during primary PCI.

DESIGN, SETTING, AND PARTICIPANTS:

Multicenter, open-label trial involving 2194 patients with AMI undergoing primary PCI at 82 centers in China between August 2012 and June 2013.

INTERVENTIONS:

Patients were randomly assigned to receive bivalirudin with a post-PCI infusion (n = 735), heparin alone (n = 729), or heparin plus tirofiban with a post-PCI infusion (n = 730). Among patients treated with bivalirudin, a postprocedure 1.75 mg/kg/h infusion was administered for a median of 180 minutes (IQR, 148-240 minutes).

MAIN OUTCOMES AND MEASURES:

The primary end point was 30-day net adverse clinical events, a composite of major adverse cardiac or cerebral events (all-cause death, reinfarction, ischemia-driven target vessel revascularization, or stroke) or bleeding. Additional prespecified safety end points included the rates of acquired thrombocytopenia at 30 days, and stent thrombosis at 30 days and 1 year.

RESULTS:

Net adverse clinical events at 30 days occurred in 65 patients (8.8%) of 735 who were treated with bivalirudin compared with 96 patients (13.2%) of 729 treated with heparin (relative risk [RR], 0.67; 95% CI, 0.50-0.90; difference, -4.3%, 95% CI, -7.5% to -1.1%; P = .008); and 124 patients (17.0%) of 730 treated with heparin plus tirofiban (RR for bivalirudin vs heparin plus tirofiban, 0.52; 95% CI, 0.39-0.69; difference, -8.1%, 95% CI, -11.6% to -4.7%; P < .001). The 30-day bleeding rate was 4.1% for bivalirudin, 7.5% for heparin, and 12.3% for heparin plus tirofiban (P < .001). There were no statistically significant differences between treatments in the 30-day rates of major adverse cardiac or cerebral events (5.0% for bivalirudin, 5.8% for heparin, and 4.9% for heparin plus tirofiban, P = .74), stent thrombosis (0.6% vs 0.9% vs 0.7%, respectively, P = .77), acquired thrombocytopenia (0.1% vs 0.7% vs 1.1%; P = .07), or in acute (<24-hour) stent thrombosis (0.3% in each group). At the 1-year follow-up, the results remained similar.

CONCLUSIONS AND RELEVANCE:

Among patients with AMI undergoing primary PCI, the use of bivalirudin with a median 3-hour postprocedure PCI-dose infusion resulted in a decrease in net adverse clinical events compared with both heparin alone and heparin plus tirofiban. This finding was primarily due to a reduction in bleeding events with bivalirudin, without significant differences in major adverse cardiac or cerebral events or stent thrombosis.

TRIAL REGISTRATION:

clinicaltrials.gov Identifier: NCT01696110.

PMID:
25775052
DOI:
10.1001/jama.2015.2323
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Silverchair Information Systems
Loading ...
Support Center